Asset Details
Do you wish to reserve the book?
Impact of intraperitoneal lavage with lobaplatin on survival in patients undergoing hepatectomy for ruptured hepatocellular carcinoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Impact of intraperitoneal lavage with lobaplatin on survival in patients undergoing hepatectomy for ruptured hepatocellular carcinoma
Do you wish to request the book?
Impact of intraperitoneal lavage with lobaplatin on survival in patients undergoing hepatectomy for ruptured hepatocellular carcinoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Impact of intraperitoneal lavage with lobaplatin on survival in patients undergoing hepatectomy for ruptured hepatocellular carcinoma
2025
Overview
Background
Intraoperative intraperitoneal lavage with lobaplatin is widely used in the treatment of colorectal and gastric cancers. This study aimed to explore the efficacy of lobaplatin lavage in patients with ruptured hepatocellular carcinoma (HCC) administered radical hepatectomy.
Methods
Ruptured HCC patients who underwent hepatectomy between September 2007 and March 2022 were divided into the distilled water lavage and lobaplatin lavage groups. Survival curves for RFS and OS were generated by the Kaplan-Meier method and compared by the log-rank test using Propensity Score Matching (PSM). Cox regression analysis was conducted to identify independent prognostic factors of RFS and OS.
Results
This study included 201 patients, with 114 cases (89.1%) in the distilled water lavage group and 55 cases (75.3%) in the lobaplatin lavage group experiencing recurrence, and 95 (74.2%) and 44 (60.3%) patients died in the distilled water lavage and lobaplatin lavage groups, respectively during the follow-up period. After PSM, 1-, 2-, 3-year RFS rates were 38.6%, 21.1%, 10.5% and 57.9%, 40.4%, 26.3% in the distilled water lavage and lobaplatin lavage groups, respectively (
P
= 0.001). 1-, 2-, 3-year OS rates were 56.1%, 40.4%, 33.3% and 89.5%, 63.2%, 43.9% in the distilled water lavage and lobaplatin lavage groups, respectively (
P
= 0.001). Multivariable Cox regression indicated that lobaplatin lavage may improve RFS (HR = 0.524, 95% CI: 0.354–0.775;
P
= 0.001) and OS (HR = 0.524, 95% CI: 0.350–0.783;
P
= 0.002).
Conclusions
Intraoperative lobaplatin lavage improves RFS and OS in patients with ruptured HCC after hepatectomy.
Trial registration
TJ-IRB202403002, 2024-04-26, retrospectively registered.
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
/ Aged
/ Antineoplastic Agents - administration & dosage
/ Antineoplastic Agents - therapeutic use
/ Cancer
/ Carcinoma, Hepatocellular - mortality
/ Carcinoma, Hepatocellular - pathology
/ Carcinoma, Hepatocellular - surgery
/ Carcinoma, Hepatocellular - therapy
/ Cyclobutanes - administration & dosage
/ Cyclobutanes - therapeutic use
/ DNA
/ Female
/ Hepatoma
/ Humans
/ Intraperitoneal lobaplatin lavage
/ Lavage
/ Male
/ Medicine
/ Neoplasm Recurrence, Local - pathology
/ Organoplatinum Compounds - administration & dosage
/ Organoplatinum Compounds - therapeutic use
/ Patients
/ Peritoneal Lavage - mortality
/ Ruptured hepatocellular carcinoma
/ Surgeons
/ Surgery
/ Survival
/ Toxicity
/ Tumors
